Cargando…

CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination

COVID-19 vaccines greatly reduce the risk of infection with SARS-CoV-2. However, some people have adverse reactions after vaccination, and these can sometimes be severe. Gender, age, vaccines, and especially certain diseases histories are related to severe adverse reactions following COVID-19 vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Jiahuan, Li, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041818/
https://www.ncbi.nlm.nih.gov/pubmed/37009244
http://dx.doi.org/10.1016/j.heliyon.2023.e14828
_version_ 1784912796938403840
author Jin, Jiahuan
Li, Jie
author_facet Jin, Jiahuan
Li, Jie
author_sort Jin, Jiahuan
collection PubMed
description COVID-19 vaccines greatly reduce the risk of infection with SARS-CoV-2. However, some people have adverse reactions after vaccination, and these can sometimes be severe. Gender, age, vaccines, and especially certain diseases histories are related to severe adverse reactions following COVID-19 vaccination. However, there are thousands of diseases and only some are known to be related to these severe adverse reactions. The risk of severe adverse reactions with other diseases remains unknown. Therefore, there is a need for predictive studies to provide improved medical care and minimize risk. Herein, we analyzed the statistical results of existing COVID-19 vaccine adverse reaction data and proposed a COVID-19 vaccine severe adverse reaction risk prediction method, named CVSARRP. The performance of the CVSARRP method was tested using the leave-one-out cross-validation approach. The correlation coefficient between the predicted and real risk is greater than 0.86. The CVSARRP method predicts the risk from adverse reactions to severe adverse reactions after COVID-19 vaccination for 10855 diseases. People with certain diseases, such as central nervous system diseases, heart diseases, urinary system disease, anemia, cancer, and respiratory tract disease, among others, may potentially have increased of severe adverse reactions following vaccination against COVID-19 and experiencing adverse events.
format Online
Article
Text
id pubmed-10041818
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100418182023-03-27 CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination Jin, Jiahuan Li, Jie Heliyon Review Article COVID-19 vaccines greatly reduce the risk of infection with SARS-CoV-2. However, some people have adverse reactions after vaccination, and these can sometimes be severe. Gender, age, vaccines, and especially certain diseases histories are related to severe adverse reactions following COVID-19 vaccination. However, there are thousands of diseases and only some are known to be related to these severe adverse reactions. The risk of severe adverse reactions with other diseases remains unknown. Therefore, there is a need for predictive studies to provide improved medical care and minimize risk. Herein, we analyzed the statistical results of existing COVID-19 vaccine adverse reaction data and proposed a COVID-19 vaccine severe adverse reaction risk prediction method, named CVSARRP. The performance of the CVSARRP method was tested using the leave-one-out cross-validation approach. The correlation coefficient between the predicted and real risk is greater than 0.86. The CVSARRP method predicts the risk from adverse reactions to severe adverse reactions after COVID-19 vaccination for 10855 diseases. People with certain diseases, such as central nervous system diseases, heart diseases, urinary system disease, anemia, cancer, and respiratory tract disease, among others, may potentially have increased of severe adverse reactions following vaccination against COVID-19 and experiencing adverse events. Elsevier 2023-03-27 /pmc/articles/PMC10041818/ /pubmed/37009244 http://dx.doi.org/10.1016/j.heliyon.2023.e14828 Text en © 2023 The Authors
spellingShingle Review Article
Jin, Jiahuan
Li, Jie
CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination
title CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination
title_full CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination
title_fullStr CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination
title_full_unstemmed CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination
title_short CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination
title_sort cvsarrp: a framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after covid-19 vaccination
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041818/
https://www.ncbi.nlm.nih.gov/pubmed/37009244
http://dx.doi.org/10.1016/j.heliyon.2023.e14828
work_keys_str_mv AT jinjiahuan cvsarrpaframeworktopredicttheriskofadversetosevereadversereactionsfor10855diseasesaftercovid19vaccination
AT lijie cvsarrpaframeworktopredicttheriskofadversetosevereadversereactionsfor10855diseasesaftercovid19vaccination